Unveiling the Heart of CAR-T Therapy: Severe Cardiovascular Events and Patient Outcomes

A groundbreaking multicenter study explores the association between severe cardiovascular events (SCEs) and mortality in patients undergoing anti-CD19 CAR-T therapy. Findings reveal significantly higher overall and nonrelapse mortality rates, as well as elevated levels of inflammatory biomarkers.